Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$22.08M
TTM
Current Assets
Q4 2024
Current Liabilities
Q4 2024
Current Ratio
2548.17%
Q4 2024
Total Assets
Q4 2024
Total Liabilities
Q4 2024
Book Value
$75.94M
Q4 2024
Cash
Q4 2024
P/E
-10.36
Nov 29, 2024 EST
Free Cash Flow
-$9.640M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000
Revenue $0.00 $75.00K $73.00K $59.00K $102.0K $12.20M $3.580M $8.360M $2.950M $2.830M $1.260M $1.500M $520.0K $340.0K $160.0K $270.0K $500.0K $380.0K $2.830M $910.0K $510.0K $430.0K $160.0K $130.0K $430.0K
YoY Change -100.0% 2.74% 23.73% -42.16% -99.16% 240.75% -57.18% 183.39% 4.24% 124.6% -16.0% 188.46% 52.94% 112.5% -40.74% -46.0% 31.58% -86.57% 210.99% 78.43% 18.6% 168.75% 23.08% -69.77%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000
Revenue $0.00 $75.00K $73.00K $59.00K $102.0K $12.20M $3.580M $8.360M $2.950M $2.830M $1.260M $1.500M $520.0K $340.0K $160.0K $270.0K $500.0K $380.0K $2.830M $910.0K $510.0K $430.0K $160.0K $130.0K $430.0K
Cost Of Revenue -$108.0K $0.00 $9.000K $123.0K -$190.0K $440.0K $350.0K $200.0K $100.0K $30.00K $180.0K $30.00K $120.0K $30.00K $40.00K $70.00K $100.0K $90.00K $370.0K $0.00 $0.00 $120.0K $310.0K $390.0K
Gross Profit $108.0K $80.00K $64.00K -$64.00K $290.0K $11.43M $3.230M $8.150M $2.850M $2.790M $1.080M $1.470M $400.0K $310.0K $120.0K $200.0K $400.0K $290.0K $2.470M $510.0K $430.0K $50.00K -$180.0K $40.00K
Gross Profit Margin 106.67% 87.67% -108.47% 284.31% 93.7% 90.22% 97.49% 96.61% 98.59% 85.71% 98.0% 76.92% 91.18% 75.0% 74.07% 80.0% 76.32% 87.28% 100.0% 100.0% 31.25% -138.46% 9.3%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000
Selling, General & Admin $6.989M $6.380M $6.646M $6.512M $5.570M $6.800M $6.760M $6.850M $10.04M $6.770M $4.400M $3.730M $3.270M $1.930M $1.300M $1.250M $2.190M $1.320M $1.850M $3.850M $6.160M $5.020M $580.0K $570.0K $680.0K
YoY Change 9.55% -4.0% 2.06% 16.91% -18.09% 0.59% -1.31% -31.77% 48.3% 53.86% 17.96% 14.07% 69.43% 48.46% 4.0% -42.92% 65.91% -28.65% -51.95% -37.5% 22.71% 765.52% 1.75% -16.18%
% of Gross Profit 6471.3% 7975.0% 10384.38% 1920.69% 59.49% 209.29% 84.05% 352.28% 242.65% 407.41% 253.74% 817.5% 622.58% 1083.33% 625.0% 547.5% 455.17% 74.9% 1207.84% 1167.44% 1160.0% 1700.0%
Research & Development $15.61M $12.77M $11.27M $7.020M $3.001M $4.567M $5.340M $5.220M $9.670M $5.180M $3.450M $1.310M $1.350M $1.260M $1.070M $830.0K $670.0K $580.0K $930.0K $2.300M
YoY Change 22.19% 13.33% 60.57% 133.92% -34.29% -14.48% 2.3% -46.02% 86.68% 50.14% 163.36% -2.96% 7.14% 17.76% 28.92% 23.88% 15.52% -37.63% -59.57%
% of Gross Profit 14452.78% 15967.5% 17612.5% 1034.83% 39.96% 165.33% 64.05% 339.3% 185.66% 319.44% 89.12% 337.5% 406.45% 891.67% 415.0% 167.5% 200.0% 37.65%
Depreciation & Amortization $87.00K $136.0K $167.0K $231.0K $190.0K $158.0K $150.0K $160.0K $10.00K $30.00K $10.00K $10.00K $0.00 $0.00 $0.00
YoY Change -36.03% -18.56% -27.71% 21.58% 20.25% 5.33% -6.25% -66.67% 200.0% 0.0%
% of Gross Profit 80.56% 170.0% 260.94% 65.52% 1.38% 4.64% 1.96% 0.93% 2.04% 2.5% 3.23% 0.0% 0.0% 0.0%
Operating Expenses $22.49M $19.16M $17.93M $13.53M $8.383M $9.616M $12.25M $12.24M $19.71M $11.95M $7.850M $5.070M $4.640M $3.200M $2.380M $2.080M $2.870M $1.910M $2.780M $6.240M $6.040M $5.120M $550.0K $590.0K $670.0K
YoY Change 17.4% 6.86% 32.48% 61.42% -12.82% -21.5% 0.08% -37.9% 64.94% 52.23% 54.83% 9.27% 45.0% 34.45% 14.42% -27.53% 50.26% -31.29% -55.45% 3.31% 17.97% 830.91% -6.78% -11.94%
Operating Profit -$22.49M -$19.08M -$17.85M -$13.60M -$8.281M $2.583M -$9.020M -$4.090M -$16.86M -$9.160M -$6.770M -$3.600M -$4.240M -$2.890M -$2.260M -$1.880M -$2.470M -$1.620M -$310.0K -$5.530M -$4.690M -$500.0K -$770.0K -$630.0K
YoY Change 17.87% 6.87% 31.32% 64.18% -420.6% -128.64% 120.54% -75.74% 84.06% 35.3% 88.06% -15.09% 46.71% 27.88% 20.21% -23.89% 52.47% 422.58% 17.91% 838.0% -35.06% 22.22%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000
Interest Expense $904.0K -$33.00K -$32.00K -$323.0K $62.00K $122.0K $0.00 -$200.0K -$300.0K $480.0K -$100.0K $1.560M $0.00 $60.00K -$60.00K $0.00 -$10.00K $40.00K -$50.00K -$10.00K -$30.00K -$100.0K -$80.00K -$60.00K -$70.00K
YoY Change -2839.39% 3.13% -90.09% -620.97% -49.18% -100.0% -33.33% -162.5% -580.0% -106.41% -100.0% -200.0% -100.0% -125.0% -180.0% 400.0% -66.67% -70.0% 25.0% 33.33% -14.29%
% of Operating Profit 4.72%
Other Income/Expense, Net $739.0K -$481.0K -$354.0K $37.00K $7.000K $26.00K
YoY Change -253.64% 35.88% -1056.76% 428.57% -73.08%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000
Pretax Income -$21.04M -$18.95M -$17.37M -$13.88M -$299.0K $169.0K -$9.020M -$4.290M -$18.03M -$9.570M -$6.880M -$3.580M -$4.240M -$3.490M -$4.080M -$1.880M -$2.480M -$1.580M -$370.0K -$5.340M -$5.560M -$4.790M -$590.0K -$830.0K -$700.0K
YoY Change 10.99% 9.12% 25.12% 4542.81% -276.92% -101.87% 110.26% -76.21% 88.4% 39.1% 92.18% -15.57% 21.49% -14.46% 117.02% -24.19% 56.96% 327.03% -93.07% -3.96% 16.08% 711.86% -28.92% 18.57%
Income Tax $0.00 $0.00 $0.00 $0.00 $0.00 -$420.0K $0.00 $0.00 $0.00 $0.00 -$70.00K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$21.75M -$19.56M -$18.21M -$13.88M -$8.274M $2.609M -$9.020M -$4.290M -$18.03M -$9.570M -$6.460M -$3.580M -$4.240M -$3.490M -$4.080M -$1.820M -$2.480M -$2.160M -$5.740M -$10.67M -$5.560M -$4.790M -$590.0K -$830.0K -$700.0K
YoY Change 11.19% 7.44% 31.16% 67.78% -417.13% -128.92% 110.26% -76.21% 88.4% 48.14% 80.45% -15.57% 21.49% -14.46% 124.18% -26.61% 14.81% -62.37% -46.2% 91.91% 16.08% 711.86% -28.92% 18.57%
Net Earnings / Revenue -26082.67% -24942.47% -23528.81% -8111.76% 21.39% -251.96% -51.32% -611.19% -338.16% -512.7% -238.67% -815.38% -1026.47% -2550.0% -674.07% -496.0% -568.42% -202.83% -1172.53% -1090.2% -1113.95% -368.75% -638.46% -162.79%
Basic Earnings Per Share -$5.51 -$14.12 -$2.23 -$3.23
Diluted Earnings Per Share -$5.51 -$14.12 -$2.23 -$3.232M -$8.108M $17.10K -$64.29K -$24.22K -$125.5K -$82.06K -$70.76K -$85.06K -$110.6K -$166.5K -$213.4K -$118.3K -$171.3K -$202.6K -$700.9K -$1.933M -$1.444M -$1.447M -$102.8K -$136.7K -$184.2K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

No data

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000
Cash & Short-Term Investments $2.480M $4.062M $19.77M $9.800M $15.86M $12.00M $13.43M $13.58M $16.78M $29.57M $1.450M $3.150M $7.130M $550.0K $1.510M $1.770M $4.210M $670.0K $4.630M $3.290M $140.0K $960.0K $0.00 $10.00K
YoY Change -38.95% -79.45% 101.72% -38.21% 32.17% -10.65% -1.1% -19.07% -43.25% 1939.31% -53.97% -55.82% 1196.36% -63.58% -14.69% -57.96% 528.36% -85.53% 40.73% 2250.0% -85.42% -100.0%
Cash & Equivalents $2.480M $4.062M $0.00 $4.570M $15.73M $11.91M $13.35M $13.58M
Short-Term Investments $130.0K $100.0K $80.00K $16.08M $29.30M $890.0K $2.610M $7.060M $400.0K $1.330M $1.570M
Other Short-Term Assets $1.190M $755.0K $814.0K $950.0K $380.0K $310.0K $220.0K $130.0K $2.430M $2.800M $20.00K $20.00K $40.00K $20.00K $10.00K $40.00K $10.00K $50.00K $550.0K $40.00K $10.00K $30.00K $0.00
YoY Change 57.62% -7.25% -14.32% 150.0% 22.58% 40.91% 69.23% -94.65% -13.21% 13900.0% 0.0% -50.0% 100.0% 100.0% -75.0% 300.0% -80.0% -90.91% 1275.0% 300.0% -66.67%
Inventory $0.00 $0.00 $190.0K $270.0K $10.00K
Prepaid Expenses
Receivables $60.00K $3.000K $25.00K $60.00K $2.540M $3.150M $3.390M $730.0K $110.0K $100.0K $130.0K $160.0K $290.0K $90.00K $110.0K $210.0K $980.0K $80.00K $30.00K $60.00K $30.00K $10.00K $730.0K
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $10.00K $0.00
Total Short-Term Assets $3.730M $4.820M $20.61M $10.81M $18.77M $15.47M $17.03M $14.44M $19.31M $32.48M $1.570M $3.300M $7.330M $860.0K $1.600M $1.920M $4.420M $1.700M $5.260M $3.360M $210.0K $1.200M $290.0K $750.0K
YoY Change -22.61% -76.61% 90.64% -42.41% 21.33% -9.16% 17.94% -25.22% -40.55% 1968.79% -52.42% -54.98% 752.33% -46.25% -16.67% -56.56% 160.0% -67.68% 56.55% 1500.0% -82.5% 313.79% -61.33%
Property, Plant & Equipment $610.0K $993.0K $577.0K $770.0K $470.0K $240.0K $340.0K $380.0K $350.0K $40.00K $30.00K $30.00K $30.00K $10.00K $10.00K $10.00K $10.00K $0.00 $680.0K $220.0K $140.0K $240.0K $150.0K $260.0K
YoY Change -38.57% 72.1% -25.06% 63.83% 95.83% -29.41% -10.53% 8.57% 775.0% 33.33% 0.0% 0.0% 200.0% 0.0% 0.0% 0.0% -100.0% 209.09% 57.14% -41.67% 60.0% -42.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $10.00K $10.00K $90.00K $50.00K $0.00 $0.00 $0.00 $0.00 $510.0K $0.00
YoY Change 0.0% -88.89% 80.0% -100.0%
Other Assets $120.0K $160.0K $194.0K $10.00K $0.00 $20.00K $30.00K $200.0K $390.0K
YoY Change -25.0% -17.53% 1840.0% -100.0% -33.33% -85.0% -48.72%
Total Long-Term Assets $730.0K $1.153M $771.0K $780.0K $480.0K $330.0K $390.0K $380.0K $350.0K $50.00K $30.00K $30.00K $30.00K $10.00K $10.00K $10.00K $10.00K $0.00 $680.0K $15.45M $9.440M $8.500M $930.0K $720.0K
YoY Change -36.69% 49.55% -1.15% 62.5% 45.45% -15.38% 2.63% 8.57% 600.0% 66.67% 0.0% 0.0% 200.0% 0.0% 0.0% 0.0% -100.0% -95.6% 63.67% 11.06% 813.98% 29.17%
Total Assets $4.460M $5.973M $21.38M $11.59M $19.25M $15.80M $17.42M $14.82M $19.66M $32.53M $1.600M $3.330M $7.360M $870.0K $1.610M $1.930M $4.430M $1.700M $5.940M $18.81M $9.650M $9.700M $1.220M $1.470M
YoY Change
Accounts Payable $1.140M $422.0K $274.0K $280.0K $1.470M $1.760M $710.0K $620.0K $590.0K $540.0K $260.0K $380.0K $500.0K $580.0K $110.0K $200.0K $650.0K $1.000M $620.0K $780.0K $350.0K $400.0K $80.00K $130.0K
YoY Change 170.14% 54.01% -2.14% -80.95% -16.48% 147.89% 14.52% 5.08% 9.26% 107.69% -31.58% -24.0% -13.79% 427.27% -45.0% -69.23% -35.0% 61.29% -20.51% 122.86% -12.5% 400.0% -38.46%
Accrued Expenses $2.770M $2.039M $921.0K $600.0K $140.0K $90.00K $60.00K $60.00K
YoY Change 35.85% 121.39% 53.5% 328.57% 50.0% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $160.0K $0.00 $0.00 $0.00 $1.900M $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due $0.00 $40.00K $0.00 $30.00K $2.210M $0.00 $10.00K $20.00K
YoY Change -100.0% -98.64% -100.0% -50.0%
Total Short-Term Liabilities $3.980M $2.532M $1.369M $1.140M $2.640M $1.890M $860.0K $770.0K $1.260M $900.0K $1.010M $600.0K $1.280M $810.0K $400.0K $640.0K $1.340M $1.650M $2.730M $1.900M $5.000M $690.0K $700.0K $1.070M
YoY Change 57.19% 84.95% 20.09% -56.82% 39.68% 119.77% 11.69% -38.89% 40.0% -10.89% 68.33% -53.13% 58.02% 102.5% -37.5% -52.24% -18.79% -39.56% 43.68% -62.0% 624.64% -1.43% -34.58%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $310.0K $390.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $480.0K $0.00 $70.00K
YoY Change -100.0% -20.51% -100.0% -100.0%
Other Long-Term Liabilities $280.0K $559.0K $0.00 $210.0K $0.00 $40.00K $30.00K $10.00K $0.00 $180.0K $260.0K $280.0K $0.00 $0.00 $0.00 $0.00 $10.00K $10.00K $50.00K
YoY Change -49.91% -100.0% -100.0% 33.33% 200.0% -100.0% -30.77% -7.14% -100.0% 0.0% -80.0%
Total Long-Term Liabilities $280.0K $559.0K $0.00 $210.0K $0.00 $40.00K $30.00K $10.00K $0.00 $0.00 $0.00 $0.00 $490.0K $650.0K $280.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $490.0K $10.00K $120.0K
YoY Change -49.91% -100.0% -100.0% 33.33% 200.0% -100.0% -24.62% 132.14% -100.0% 4800.0% -91.67%
Total Liabilities $4.260M $3.091M $1.369M $1.350M $2.640M $1.920M $890.0K $780.0K $1.260M $900.0K $1.010M $600.0K $1.780M $1.460M $680.0K $640.0K $1.340M $1.650M $2.730M $1.900M $5.000M $1.180M $710.0K $1.190M
YoY Change 37.82% 125.79% 1.41% -48.86% 37.5% 115.73% 14.1% -38.1% 40.0% -10.89% 68.33% -66.29% 21.92% 114.71% 6.25% -52.24% -18.79% -39.56% 43.68% -62.0% 323.73% 66.2% -40.34%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000
Basic Shares Outstanding 4.060M 1.386M 8.172M 4.295M
Diluted Shares Outstanding 4.060M 1.386M 8.172M 4.295M
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $228.68 Million

About Benitec Biopharma Inc.

Benitec Biopharma, Inc. is a development-stage biotechnology company, which engages in the advancement of novel genetic medicines. The company is headquartered in Hayward, California and currently employs 16 full-time employees. The company went IPO on 2012-07-11. The firm is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The firm is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.

Industry: Pharmaceutical Preparations Peers: Acorda Therapeutics, Inc. Cibus, Inc. Sonnet BioTherapeutics Holdings, Inc. Statera Biopharma, Inc. Ensysce Biosciences, Inc. EXICURE, INC. Xenetic Biosciences, Inc. NAVIDEA BIOPHARMACEUTICALS, INC. Phio Pharmaceuticals Corp.